American Journal of Psychiatry · 1961 · 56 citations · 4 references
MedicinePharmacologyPharmacotherapyDementiaNeuropharmacologyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyDementia PharmacotherapyDrug-induced Movement DisordersPsychiatric Effects Of MedicationsSchizophrenia PharmacotherapyAntipsychotic Medication ManagementDaily DosingMedication-induced Neuropsychiatric Effects
In 3 patients suffering from schizophrenia and one patient with arteriosclerotic dementia persisting dyskinetic movements caused by psychopharmaca disappeared almost or completely after treatment with tetrabenacine (Nitoman®). The schizophrenics received a daily dose of 75 mg., whereas it was necessary to give the patient with dementia 150-300 mg. per day in order to obtain a satisfactory effect. This patient responded by developing a certain degree of drowsiness, while no side effects were observed in the other cases.
4